Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 $10 ...

The Massachusetts-based company said that third-quarter revenue from its Spikevax shot came in at $1.8 billion, with $1.2 billion of the sales coming in the United States. The overall figure ...

Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial.

The suits allege that nanoparticles used in Moderna's Spikevax COVID-19 shot and recently approved mResvia vaccine for RSV – which competes with GSK's $1.7 billion blockbuster Arexvy ...